卵巢上皮性癌组织中的Pax-5和miR-215表达水平及临床意义-现代医学

卵巢上皮性癌组织中的Pax-5和miR-215表达水平及临床意义

单位：1. 河北北方学院附属第一医院妇产科, 河北张家口 075000;
2. 邯郸市妇幼保健院妇产科, 河北邯郸 056002

分类号：R737.31

出版年·卷·期（页码）：2020·48·第一期（15-20）

摘要：

目的： 研究Pax-5和miR-215在卵巢上皮性癌组织中的表达水平，并探讨其与患者预后的关系。方法： 收集行手术切除的卵巢上皮性癌组织和正常卵巢上皮组织各80例，采用实时荧光定量PCR（RT-PCR）法检测组织中Pax-5和miR-215表达水平，采用Pearson相关系数（r）法分析Pax-5和miR-215的相关性，并分析Pax-5、miR-215表达与卵巢上皮性癌临床病理特征的关系；采用Kaplan-Meier（K-M）生存曲线分析Pax-5和miR-215不同表达水平对患者无瘤生存率的影响，COX回归模型用于分析影响卵巢上皮性癌无瘤生存期的危险因素。方法： 卵巢上皮性癌组织中Pax-5和miR-215表达水平均低于正常卵巢上皮组织（1.39±0.36）vs（2.03±0.54）、（0.92±0.27）vs（1.36±0.41），差异有统计学意义（P < 0.05）；卵巢上皮性癌组织中Pax-5和miR-215呈正相关（r=0.677，P=0.010）；Pax-5表达水平与卵巢上皮性癌淋巴结转移（1.30±0.29） vs （1.53±0.33）、肿瘤大小（1.32±0.25） vs （1.46±0.31）和术后复发情况（1.29±0.18） vs （1.44±0.32）有关（P < 0.05），miR-215与卵巢上皮性癌FIGO分期（0.97±0.20） vs （0.85±0.23）、淋巴结转移（0.83±0.19） vs （1.06±0.24）、肿瘤大小（0.86±0.20） vs （0.97±0.21）和术后复发情况（0.79±0.18） vs （0.98±0.23）有关（P < 0.05）；Pax-5高表达组患者无瘤生存率高于Pax-5低表达组（P < 0.05），miR-215高表达组患者无瘤生存率高于miR-215低表达组（P < 0.05）；淋巴结转移、肿瘤大小、术后复发情况和肿瘤组织中Pax-5、miR-215表达水平是影响卵巢上皮性癌术后无瘤生存期的独立危险因素（OR=3.792，3.309，4.276，2.692，2.090，P均 < 0.05）。方法： Pax-5和miR-215在卵巢上皮性癌组织中表达下调，与卵巢上皮性癌增殖、转移等恶性行为及不良预后有关。

Objective: To investigate the expressions of Pax-5 and miR-215 in epithelial ovarian cancer tissues and their relationships with prognosis. Methods: 80 cases of epithelial ovarian cancer tissues and normal epithelial tissues were collected, the expression levels of Pax-5 and miR-215 in tissues were detected by real-time fluorescence quantitative PCR (RT-PCR). Pearson correlation coefficient (r) method was used to analyze the correlation between Pax-5 and microRNA-215 in epithelial ovarian cancer and their relationships with clinicopathological characteristics. Kaplan-Meier (K-M) survival curve was used to analyze the effect of Pax-5 and miR-215 expression levels on the tumor-free survival rate of patients. COX regression model was used to analyze the risk factors affecting the tumor-free survival of epithelial ovarian cancer. Results: The expression levels of Pax-5 and miR-215 in epithelial ovarian cancer tissues were lower than those in normal ovarian epithelial tissues (1.39±0.36) vs(2.03±0.54),(0.92±0.27) vs (1.36±0.41), the difference was significant (P<0.05); Pax-5 and miR-215 were positively correlated in epithelial ovarian cancer(r=0.677, P=0.010); the expression of Pax-5 was correlated with lymph node metastasis(1.30±0.29) vs (1.53±0.33), tumor size (1.32±0.25) vs (1.46±0.31) and postoperative recurrence (1.29±0.18) vs (1.44±0.32) in epithelial ovarian cancer (P<0.05), the expressions of miR-215 was correlated with FIGO stage (0.97±0.20) vs (0.85±0.23), lymph node metastasis (0.83±0.19) vs (1.06±0.24), tumor size (0.86±0.20) vs (0.97±0.21) and postoperative recurrence(0.79±0.18) vs (0.98±0.23) (P<0.05); the tumor-free survival rate of patients with higher expression of Pax-5 was higher than those with lower expression of Pax-5 (P<0.05), the tumor-free survival rate of patients with higher expression of miR-215 was higher than those of lower expression of miR-215 (P<0.05); lymph node metastasis, tumor size, postoperative recurrence and the expressions of Pax-5 and miR-215 were independent risk factors for postoperative tumor-free survival after epithelial ovarian cancer surgery (OR=3.792, 3.309, 4.276, 2.692, 2.090, P<0.05). Conclusion: The expressions of Pax-5 and miR-215 are down-regulated in epithelial ovarian cancer tissue, which is related to malignant behaviors such as proliferation, metastasis and poor prognosis of epithelial ovarian cancer.

参考文献：

[1] NUTT S L,HEAVEY B,ROLINK A G,et al.Commitment to the B-lymphoid lineage depends on the transcription factor Pax5[J].Nature,2015,401(6753):556-562.
[2] 李学锋,朱梅刚,丁向东,等.B细胞特异性激活蛋白PAX-5在间变性大细胞淋巴瘤中的异常表达及意义[J].实用医学杂志,2018,34(2):305-308.
[3] BENZINA S,HARQUAIL J,GUERRETTE R,et al.Breast cancer malignant processes are regulated by Pax-5 through the disruption of FAK signaling pathways[J].J Cancer,2016,7(14):2035-2044.
[4] HARQUAIL J,LEBLANC N,LANDRY C,et al.Pax-5,inhibits NF-κB activity in breast cancer cells through IKKε and miRNA-155 effectors[J].J Mammary Gland Biol Neoplasia,2018,23(3):177-187.
[5] YANG L,YANG J,XU T,et al.microRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer[J].Am J Transl Res,2017,9(2):466-477.
[6] ZEPPERNICK F,MEINHOLD-HEERLEIN I.The new FIGO staging system for ovarian,fallopian tube,and primary peritoneal cancer[J].Arch Gynecol Obstet,2014,290(5):839-842.
[7] 张爽爽,夏庆民,郑荣寿,等.中国2010年卵巢癌发病与死亡分析[J].中国肿瘤,2016,25(3):169-173.
[8] ARUN I,ROY P,ARORA N,et al.PAX-5 Positivity in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma[J].Int J Surg Pathol,2016,25(4):333-338.
[9] 叶郁红,张声,叶建刚,等.PAX-5、CD117、PDGFRA在胃肠道神经内分泌肿瘤中的表达及意义[J].中国组织化学与细胞化学杂志,2014,23(3):252-256.
[10] BENZINA S,BEAUREGARD A P,GUERRETTE R,et al.Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes[J].Oncotarget,2017,8(7):12052-12066.
[11] BRACKEN C P,SCOTT H S,GOODALL G J.A network-biology perspective of microRNA function and dysfunction in cancer[J].Nat Rev Genet,2016,17(12):719-732.
[12] 马瀚博,李怀芳.microRNA在卵巢癌早期诊断及预后中应用的研究进展[J].中华全科医学,2018,16(5):826-829.
[13] GE G,ZHANG W,NIU L,et al.miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis[J].Oncol Rep,2015,35(3):1816-1822.
[14] 方回,庞湃,刘法昱,等.转录因子特异蛋白1在头颈部鳞状细胞癌中参与微RNA-92b转录调节的研究[J].中华口腔医学杂志,2017,52(9):563-568.
[15] 毛竹君,祝利民,卢艳琳,等.miRNA通过转录因子及EMT相关调控蛋白在胃癌侵袭转移中的作用机制研究[J].癌症进展,2019,17(8):890-892.
[16] LEBLANC N,HARQUAIL J,CRAPOULET N,et al.Pax-5 inhibits breast cancer proliferation through miR-215 up-regulation[J].Anticancer Res,2018,38(1):5013-5026
[17] 董小丽,赵恩锋.上皮-间质型循环肿瘤细胞在卵巢癌复发转移中的作用[J].解放军医学杂志,2016,41(9):788-791.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录